Double-Dose drug combo tested for Tough-to-Treat lung cancer
NCT ID NCT05263947
Summary
This study tested whether combining two existing cancer drugs—bevacizumab and a double dose of icotinib—works better than standard treatment for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR L858R mutation). The trial involved 35 adults who had not yet received treatment for their advanced cancer. The goal was to see if this combination could better control the cancer and delay its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.